Acorda Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACOR Nasdaq 8731 http://www.acorda.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acorda Therapeutics Inc

Acorda Therapeutics to Present at Sequire Biotechnology Conference - Jan 31st, 2023 9:01 pm
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA® - Jan 5th, 2023 9:20 pm
Acorda Therapeutics Announces Revised Long-Term Financial Guidance - Dec 22nd, 2022 1:00 pm
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing - Dec 20th, 2022 10:30 pm
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash - Dec 5th, 2022 12:01 pm
Acorda Therapeutics Third Quarter 2022 Earnings: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021) - Nov 19th, 2022 1:12 pm
Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders - Nov 11th, 2022 2:52 pm
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders - Nov 4th, 2022 1:25 pm
Acorda Therapeutics Reports Third Quarter 2022 Financial Results - Nov 1st, 2022 8:01 pm
Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance - Oct 27th, 2022 11:00 am
Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022 - Oct 25th, 2022 8:01 pm
Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D. - Oct 21st, 2022 11:00 am
ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split - Oct 19th, 2022 11:00 am
Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt - Oct 18th, 2022 11:00 am
Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case - Oct 16th, 2022 8:48 pm
Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders - Oct 10th, 2022 10:30 am
Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Sep 8th, 2022 8:01 pm
Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals - Aug 29th, 2022 11:00 am
Acorda Therapeutics Announces Resignation of Chief Operating Officer - Aug 19th, 2022 12:00 pm
Acorda Therapeutics Reports Second Quarter 2022 Financial Results - Aug 4th, 2022 8:01 pm